Proteasome-targeted therapies in cancer

Vasudha Tandon; Jack Molyneux; Amy Dunne Miller; Nilabja Sikdar; Sourav Banerjee

doi:10.1016/B978-0-443-26635-5.00057-2

Proteasome-targeted therapies in cancer

Vasudha Tandon
, Jack Molyneux
, Amy Dunne Miller
, Nilabja Sikdar
, Sourav Banerjee

Cancer Research

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

The function of the proteasome is to recycle misfolded/polyubiquitinated proteins into small peptide fragments which can then be reused by the cell. It was found that cancers have upregulated proteasome subunits and became a therapeutic target. In this chapter we will explore how proteasome inhibitors came about to be, which proteasome inhibitors have been approved for which cancer, why proteasome inhibitors are a target for certain cancers, how cancer cells can become resistant to proteasome inhibitors, other ways we can potentially target the ubiquitin proteasome pathway, and the many ways we can potentially bypass proteasome inhibitor resistance.

Original language	English
Title of host publication	Therapeutics of Natural and Synthetic Compounds in Protease-Induced Cancer
Editors	Sajal Chakraborti
Place of Publication	London
Publisher	Elsevier
Chapter	12
Pages	157-175
Number of pages	19
ISBN (Electronic)	9780443266355
ISBN (Print)	9780443266362
DOIs	https://doi.org/10.1016/B978-0-443-26635-5.00057-2
Publication status	Published - 26 Sept 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

bortezomib
cancer
inhibitors
multiple myeloma
Proteasome
resistance
ubiquitin proteasome pathway

ASJC Scopus subject areas

General Agricultural and Biological Sciences
General Biochemistry,Genetics and Molecular Biology

Access to Document

10.1016/B978-0-443-26635-5.00057-2

Cite this

@inbook{4af27d8261ba4829a33416429e45ad4d,

title = "Proteasome-targeted therapies in cancer",

abstract = "The function of the proteasome is to recycle misfolded/polyubiquitinated proteins into small peptide fragments which can then be reused by the cell. It was found that cancers have upregulated proteasome subunits and became a therapeutic target. In this chapter we will explore how proteasome inhibitors came about to be, which proteasome inhibitors have been approved for which cancer, why proteasome inhibitors are a target for certain cancers, how cancer cells can become resistant to proteasome inhibitors, other ways we can potentially target the ubiquitin proteasome pathway, and the many ways we can potentially bypass proteasome inhibitor resistance.",

keywords = "bortezomib, cancer, inhibitors, multiple myeloma, Proteasome, resistance, ubiquitin proteasome pathway",

author = "Vasudha Tandon and Jack Molyneux and Miller, \{Amy Dunne\} and Nilabja Sikdar and Sourav Banerjee",

year = "2025",

month = sep,

day = "26",

doi = "10.1016/B978-0-443-26635-5.00057-2",

language = "English",

isbn = "9780443266362",

pages = "157--175",

editor = "Sajal Chakraborti",

booktitle = "Therapeutics of Natural and Synthetic Compounds in Protease-Induced Cancer",

publisher = "Elsevier",

address = "Netherlands",

}

TY - CHAP

T1 - Proteasome-targeted therapies in cancer

AU - Tandon, Vasudha

AU - Molyneux, Jack

AU - Miller, Amy Dunne

AU - Sikdar, Nilabja

AU - Banerjee, Sourav

PY - 2025/9/26

Y1 - 2025/9/26

N2 - The function of the proteasome is to recycle misfolded/polyubiquitinated proteins into small peptide fragments which can then be reused by the cell. It was found that cancers have upregulated proteasome subunits and became a therapeutic target. In this chapter we will explore how proteasome inhibitors came about to be, which proteasome inhibitors have been approved for which cancer, why proteasome inhibitors are a target for certain cancers, how cancer cells can become resistant to proteasome inhibitors, other ways we can potentially target the ubiquitin proteasome pathway, and the many ways we can potentially bypass proteasome inhibitor resistance.

AB - The function of the proteasome is to recycle misfolded/polyubiquitinated proteins into small peptide fragments which can then be reused by the cell. It was found that cancers have upregulated proteasome subunits and became a therapeutic target. In this chapter we will explore how proteasome inhibitors came about to be, which proteasome inhibitors have been approved for which cancer, why proteasome inhibitors are a target for certain cancers, how cancer cells can become resistant to proteasome inhibitors, other ways we can potentially target the ubiquitin proteasome pathway, and the many ways we can potentially bypass proteasome inhibitor resistance.

KW - bortezomib

KW - cancer

KW - inhibitors

KW - multiple myeloma

KW - Proteasome

KW - resistance

KW - ubiquitin proteasome pathway

UR - https://www.scopus.com/pages/publications/105036910597

U2 - 10.1016/B978-0-443-26635-5.00057-2

DO - 10.1016/B978-0-443-26635-5.00057-2

M3 - Chapter

AN - SCOPUS:105036910597

SN - 9780443266362

SP - 157

EP - 175

BT - Therapeutics of Natural and Synthetic Compounds in Protease-Induced Cancer

A2 - Chakraborti, Sajal

PB - Elsevier

CY - London

ER -

Proteasome-targeted therapies in cancer

Abstract

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this